EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia

Federica Toscanini, Pasqualina De Leo, Giuseppe Calcagno, Federica Malfatti, Alessandro Grasso, Marco Anselmo

Case Reports in Hepatology · 2011

DOI: 10.1155/2011/258791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Case Reports in Hepatology, 2011. Verfasst von Federica Toscanini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, San Paolo Hospital, Via Genova 20, 17100 Savona, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B virus (HBV) reactivation is an increasingly recognized cause of morbidity and mortality in patients undergoing chemotherapy. In haematology, the risk of reactivation of B hepatitis among HBsAg-positive patients has been documented; therefore, use of lamivudine prophylaxis is recommended before starting chemotherapy. Differently, for HBsAg-negative patients with markers of previous HBV infection (i.e., presence of isolated anti-HBc positivity) (anticore patients) management strategies are not univocal. We describe a rare case of HBV reactivation in an anticore patient after fludarabine therapy for chronic lymphocytic leukaemia. The patient fully recovered after a 6-month course of lamivudine with persistent HBV-DNA clearance and loss of HBsAg. The most important feature of this case is that fludarabine alone infrequently determines HBV reactivation, especially in anticore patients. Therefore, we suggest that patients candidates to receive fludarabine therapy should be considered for lamivudine prophylaxis, not only if HBsAg-positive, but even if anticore-positive only.

Autor:innen und Institutionen

  • Department of Infectious Diseases, San Paolo Hospital, Via Genova 20, 17100 Savona, Italy.
  • Department of Internal Medicine and Gastroenterology, San Paolo Hospital, 17100 Savona, Italy.

Zitieren

APA

Toscanini, F., De Leo, P., Calcagno, G., Malfatti, F., Grasso, A., & Anselmo, M. (2011). Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia. Case Reports in Hepatology. https://doi.org/10.1155/2011/258791

Vancouver

Toscanini F, De Leo P, Calcagno G, Malfatti F, Grasso A, Anselmo M. Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia. Case Reports in Hepatology. 2011. doi:10.1155/2011/258791

BibTeX
@article{Toscanini2011,
  author = {Toscanini, Federica and De Leo, Pasqualina and Calcagno, Giuseppe and Malfatti, Federica and Grasso, Alessandro and Anselmo, Marco},
  title = {Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia},
  journal = {Case Reports in Hepatology},
  year = {2011},
  doi = {10.1155/2011/258791}
}
Kostenlos starten →